281 related articles for article (PubMed ID: 33674598)
21. The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation.
Owen I; Yee D; Wyne H; Perdikari TM; Johnson V; Smyth J; Kortum R; Fawzi NL; Shewmaker F
J Cell Sci; 2021 Sep; 134(17):. PubMed ID: 34357401
[TBL] [Abstract][Full Text] [Related]
22. Post-transcriptional regulation of FUS and EWS protein expression by miR-141 during neural differentiation.
Svetoni F; De Paola E; La Rosa P; Mercatelli N; Caporossi D; Sette C; Paronetto MP
Hum Mol Genet; 2017 Jul; 26(14):2732-2746. PubMed ID: 28453628
[TBL] [Abstract][Full Text] [Related]
23. Biochemical Properties and Biological Functions of FET Proteins.
Schwartz JC; Cech TR; Parker RR
Annu Rev Biochem; 2015; 84():355-79. PubMed ID: 25494299
[TBL] [Abstract][Full Text] [Related]
24. Differential transactivation by orphan nuclear receptor NOR1 and its fusion gene product EWS/NOR1: possible involvement of poly(ADP-ribose) polymerase I, PARP-1.
Ohkura N; Nagamura Y; Tsukada T
J Cell Biochem; 2008 Oct; 105(3):785-800. PubMed ID: 18680143
[TBL] [Abstract][Full Text] [Related]
25. RNA targets of wild-type and mutant FET family proteins.
Hoell JI; Larsson E; Runge S; Nusbaum JD; Duggimpudi S; Farazi TA; Hafner M; Borkhardt A; Sander C; Tuschl T
Nat Struct Mol Biol; 2011 Nov; 18(12):1428-31. PubMed ID: 22081015
[TBL] [Abstract][Full Text] [Related]
26. Differential interaction of PRMT1 with RGG-boxes of the FET family proteins EWS and TAF15.
Li KKC; Chau BL; Lee KAW
Protein Sci; 2018 Mar; 27(3):633-642. PubMed ID: 29193371
[TBL] [Abstract][Full Text] [Related]
27. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.
Yang L; Chansky HA; Hickstein DD
J Biol Chem; 2000 Dec; 275(48):37612-8. PubMed ID: 10982800
[TBL] [Abstract][Full Text] [Related]
28. Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.
Ryan JJ; Sprunger ML; Holthaus K; Shorter J; Jackrel ME
J Biol Chem; 2019 Jul; 294(29):11286-11296. PubMed ID: 31171724
[TBL] [Abstract][Full Text] [Related]
29. Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family.
Kovar H
Sarcoma; 2011; 2011():837474. PubMed ID: 21197473
[TBL] [Abstract][Full Text] [Related]
30. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
31. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.
Kim S; Denny CT; Wisdom R
Mol Cell Biol; 2006 Apr; 26(7):2467-78. PubMed ID: 16537893
[TBL] [Abstract][Full Text] [Related]
32. TAF15 and the leukemia-associated fusion protein TAF15-CIZ/NMP4 are cleaved by caspases-3 and -7.
Alves J; Wurdak H; Garay-Malpartida HM; Harris JL; Occhiucci JM; Belizário JE; Li J
Biochem Biophys Res Commun; 2009 Jul; 384(4):495-500. PubMed ID: 19426707
[TBL] [Abstract][Full Text] [Related]
33. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Zinszner H; Albalat R; Ron D
Genes Dev; 1994 Nov; 8(21):2513-26. PubMed ID: 7958914
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma.
Panagopoulos I; Mertens F; Isaksson M; Domanski HA; Brosjö O; Heim S; Bjerkehagen B; Sciot R; Dal Cin P; Fletcher JA; Fletcher CD; Mandahl N
Genes Chromosomes Cancer; 2002 Dec; 35(4):340-52. PubMed ID: 12378528
[TBL] [Abstract][Full Text] [Related]
35. Interactome analyses revealed that the U1 snRNP machinery overlaps extensively with the RNAP II machinery and contains multiple ALS/SMA-causative proteins.
Chi B; O'Connell JD; Yamazaki T; Gangopadhyay J; Gygi SP; Reed R
Sci Rep; 2018 Jun; 8(1):8755. PubMed ID: 29884807
[TBL] [Abstract][Full Text] [Related]
36. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
[TBL] [Abstract][Full Text] [Related]
37. [Functions of the FET protein family in health and disease].
Matsumoto K
Seikagaku; 2014 Apr; 86(2):274-80. PubMed ID: 24864457
[No Abstract] [Full Text] [Related]
38. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.
Panagopoulos I; Lassen C; Isaksson M; Mitelman F; Mandahl N; Aman P
Oncogene; 1997 Sep; 15(11):1357-62. PubMed ID: 9315104
[TBL] [Abstract][Full Text] [Related]
39. Aggregation of FET Proteins as a Pathological Change in Amyotrophic Lateral Sclerosis.
Furukawa Y; Tokuda E
Adv Exp Med Biol; 2017; 925():1-12. PubMed ID: 27311318
[TBL] [Abstract][Full Text] [Related]
40. RNA-binding proteins with prion-like domains in health and disease.
Harrison AF; Shorter J
Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
